p53-Adjusted Neoadjuvant Chemotherapy for potentially resectable Oesophageal Cancer pANCHO. - pANCHO

The Austrian Society of Surgical Oncology (ACO-ASSO)0 个研究点目标入组 170 人开始时间: 2007年5月16日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•- Histological verification of esophageal cancer (any subtype)
•- Presence of T2, T3, T4 or any N1 disease except patients with distant metastasis (M1)
•(potentially resectable)
•- No prior tumor therapy for esophageal cancer
•- Performance status of 0-2 on ECOG scale
•- Medical fitness of patient, including respiratory function, adequate for possible radical
•esophageal resection.
•- Males and females, age >18 to 75 years or elder patients with WHO performance
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years)
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years)
•F.1.3.1 Number of subjects for this age range

•- Inoperability (technical or functional)
•- Clinical stage cT1N0
•- Concurrent administration of any other tumor therapy, including radiotherapy, cytotoxic
•chemotherapy, immunotherapy, molecular target therapy, genetherapy.
•- Second primary malignancy that is clinically detectable at the time of consideration for
•study enrollment.

发起方

The Austrian Society of Surgical Oncology (ACO-ASSO)